Immutep Ltd · ASX:IMM
Immutep — Shareholder Meeting (November 2019)
24 slides from Immutep's shareholder meeting presentation, Nov 1, 2019
Slide 1: The global leader in developing LAG-3 therapeutics - Annual General Meeting
For personal use only The global leader in developing LAG-3 therapeutics Annual General Meeting November 2019 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: 2019 Summary
2019 Summary For personal use only • Strong operational and financial progress Ticker ASX: IMM; NASDAQ: IMMP • Continued focus on LAG-3 immunotherapy Ordinary Shares / 73% / 27% American Depository • Progressed the development of four product candidates Shares (ADSs) for cancer and autoimmune diseas
Slide 4: Corporate Highlights of past months
Corporate Highlights of past 12 months For personal use only • Sound financial management • ADR raise in Dec 2018: US$5.2million (A$7.2million) • ASX Placement and Rights Issue A$10 million, post FY19 • R&D cash incentives received from Australian & French schemes • Presentations at SITC, World Immu
Slide 5: R&D Highlights of past months
R&D Highlights of past 12 months For personal use only TACTI-mel INSIGHT • Phase I recruitment completed & positive • Phase I trial in Germany (Investigator final efficacy data reported Initiated Trial study) 13 patients recruited AIPAC INSIGHT-004 – with Merck KGaA & Pfizer • Phase IIb clinical ful
Slide 6: Collaboration Highlights of past months
Collaboration Highlights of past 12 months For personal use only Novartis • Data presentation of LAG525 at ASCO with 5 clinical trials now live GSK • Commenced Phase II clinical study evaluating GSK2831781 (derived from IMP731) in 280 ulcerative colitis patients • GSK £4million (~A$7.39 million) mil
Slide 7: Key Financials FY19
Key Financials FY19 For personal use only Revenue and other income FY19 $7.5M (FY 18 A$7.4M) Includes revenues, grants and received interest G&A Expenses FY19 $6.4M (FY 18 A$7.2M) Decrease largely due to the lower employee share-based payment expenses R&D and IP Expenses FY19 $16.6M (FY 18 A$10.0M)
Slide 8: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Company Program Preclinical Phase I Phase II Phase III Total Trials Patients on Trials Agonist Eftilagimod Alpha Eftilagimod Alpha 2 3 22 4244 424 BMS Relatlimab 6 19 2 27 9,422 Novartis LAG525 (IMP701) 1 4 1,122 LAG525 (IMP701) 1 4 5 1,100
Slide 9: Program Update
9 For personal use only Program Update
Slide 10: Immutep Controlled Immunotherapy Pipeline
Immutep Controlled Immunotherapy Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(5) Rights AIPAC (Chemo-IO Combo) Metastatic Breast Cancer TACTI-002 (1) (IO-IO Combo) NSCLC (1st/2nd L.) HNSCC (2nd) 2019 Eftilagimod Alpha Global Rights INSIGHT-004 (2), (3) (
Slide 11: Out-Licensed Immunotherapy Pipeline
Out-Licensed Immunotherapy Pipeline* For personal use only Commercial Program Preclinical Phase I Phase II Late Stage(1) Rights/Partners IO-IO Combo: Solid Tumors + Blood Cancer Chemo-IO Combo: Triple Negative Breast Cancer Oncology LAG525 Global Rights IO-IO-Small Molecule Combo: Melanoma (Antagoni
Slide 12: Lead Program Eftilagimod Alpha (IMP321) Update
For personal use only Lead Program Eftilagimod Alpha (IMP321) Update 12
Slide 13: Opportunity for Eftilagimod Alpha
Opportunity for Eftilagimod Alpha For personal use only Efti has multiple shots on goal in different indications and in different combinations • Best-and-First-In-Class MHCII agonist • Good safety profile and encouraging efficacy data thus far • Estimated favorable (low) cost of goods, current flat
Slide 14: Efti - Clinical Development AIPAC
Efti - Clinical Development AIPAC For personal use only AIPAC: Active Immunotherapy PAClitaxel in HER2-/ HR+ MBC Arm 1, 113 patients: Phase IIb, Safety-run in, paclitaxel + IMP321 multinational, Run-in: RP2D 15 (6+9) patients, Stage 2 randomized, Stage 2: Efficacy (PFS) 2 cohorts Arm 2, 113 patients
Slide 15: Treatment Landscape for HR+/HER2- MBC
Treatment Landscape for HR+/HER2- MBC For personal use only Epidemiology: • 812,500 HR+/HER2- diagnoses p.a. worldwide (1) • ~ appr 250.000 develop metastatic disease and are eligible to chemotherapy Treatment Landscape MBC (Before 2015) Treatment Landscape (Today) Treatment Landscape (Future) HR+/H
Slide 16: Efti in Melanoma: TACTI-mel Trial Design
Efti in Melanoma TACTI-mel – Trial Design For personal use only TACTI-mel: Two ACTive Immunotherapeutics in Melanoma Recommended Phase I, multicenter, 24 patients, Efti (IMP321) + Phase II dose, open label, 4 cohorts of 6 patients anti-PD-1 (Keytruda) safety and dose escalation tolerability Status
Slide 17: Efti - Clinical Development TACTI-002 (Phase II)
Efti - Clinical Development TACTI-002 (Phase II) For personal use only TACTI-002: Two ACTive Immunotherapeutics in different indications Simon’s 2 stage Efti (IMP321) + Pembrolizumab Phase II, multi- ORR, PFS, OS, PK, design; 3 indications; (Keytruda) for 12 months + 12 national (EU + US Biomarker;
Slide 18: Efti - Clinical Development INSIGHT-004 (Phase I)
Efti - Clinical Development INSIGHT-004 (Phase I) For personal use only INSIGHT-004 – Dose escalation of efti in combination with avelumab Dose escalation, Efti (IMP321) + Avelumab Phase I, solid tumors, 2 (Bavenico) for 6 months + 6 monocenter DE, RP2D, Safety, ORR, cohorts of 6 pts each months av
Slide 19: Eftilagimod Alpha Partnerships
Eftilagimod Alpha Partnerships • EOC, an Eddingpharm spin-off holding the Chinese rights for efti, Phase I study in MBC For personal use only ongoing • Milestone and royalty bearing partnership for Immutep where EOC bears all the costs of funding the trials • Spin off from NEC, Japan. Est. Dec 2016;
Slide 20: IMP761 (Autoimmune Diseases)
For personal use only IMP761 (Autoimmune Diseases) 20
Slide 21: IMP761 Summary
IMP761 Summary For personal use only • The Concept: treating the cause of autoimmune diseases, not just the symptoms • The Target: the self-peptide specific memory T cells harboring LAG-3 • The Tool: an agonistic LAG-3-specific mAb down-modulating self-peptide-induced TCR signaling • The Evidence (1
Slide 22: Outlook
22 For personal use only Outlook
Slide 23: 2019/2020 Clinical Guidance
2019/ 2020 Clinical Guidance* For personal use only Reported: Upcoming Data: ✓ TACTI-002 to commence, Phase II trial in • TACTI-002 data update: Q4 2019 collaboration with MSD: H1 2019 • INSIGHT-004 update: Q4 2019 ✓ TACTI-mel data from fourth patient cohort (30 • TACTI-mel safety data: H1 2020 mg d
Slide 24: Thank you!
24 For personal use only Thank you!